In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1852 News Items found
Dr. Rachel Grisham
FDA Approves Avutometinib-Defactinib Combination for Treating Recurrent Low-Grade Serous Ovarian Cancer With a KRAS Mutation

The FDA has approved the first-ever treatment developed for low-grade serous ovarian cancer, a rare type of ovarian cancer.
A lab coat with an MSK logo hangs on a hook
Meet the 2025 Graduates of the Gerstner Sloan Kettering Graduate School

Fourteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 14, 2025, as part of Memorial Sloan Kettering’s 46th annual academic convocation.
Patient Jason Weiner and his family
Promising New Treatment for Myelofibrosis Blood Cancer Using a Combination Targeted Therapy 

A phase 3 trial for myelofibrosis found that adding pelabresib to ruxolitinib was more effective than ruxolitinib alone and did not significantly increase side effects.
Jung Hun Oh
Pregnancy-Related Proteins in Tumors Linked to Worse Survival in Female Lung Cancer Patients

Lung cancer co-opts genes that normally help a fetus develop and evade the mother’s immune system — leading to poorer outcomes in female patients, an MSK research team has found.
Man posing with his wife, son, and daughter.
Clinical Update
Immunotherapy After Surgery Helps Prevent Cancer Recurrence in MMRd Patients With ctDNA, MSK Study Shows

Read about clinical trial results showing that a liquid biopsy helped select cancer patients for effective immunotherapy treatment.
David and Margaret
Potential New Treatment for KRAS-GI2D Lung Cancer Reported in First-of-Its-Kind Clinical Trial

For the first time, a targeted drug is showing promise at treating non-small cell lung cancer caused by a mutation called KRAS-G12D.
Maureen Sideris is seen smiling with her sister Marion.
Using Only Immunotherapy Successfully Treats Several Cancers With MMRd Mutation, Improves Quality of Life

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation, or chemotherapy.
Dr. Elli Papaemmanuil in her lab
Why Clonal Hematopoiesis, a Blood Condition Related to Aging, Is Linked to Worse Outcomes for Cancer Patients

Researchers have shown how CH, a blood condition related to aging, affects cancer outcomes — through a phenomenon called tumor-infiltrating clonal hematopoiesis.
A pipette inserted into a tube in a rack of test tubes
A New Cellular Immunotherapy Approach May Offer Treatment for AML and MDS 

Laboratory research shows how it may be possible to develop an immunotherapy-based approach for treating aggressive forms of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
A researcher working in an MSK lab
MSK Research Highlights, April 23, 2025

New MSK research identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife. MSK clinical trials also supported the recent approval of the targeted drug larotrectinib by the FDA.